Related references
Note: Only part of the references are listed.
Article
Biochemistry & Molecular Biology
Wanwisa Dejnirattisai et al.
Summary: On November 24, 2021, the sequence of a new SARS-CoV-2 variant, Omicron-B.1.1.529, was announced. Compared to previous variants, Omicron has a higher number of mutations in the Spike (S) protein. Serum neutralization of Omicron by individuals vaccinated or previously infected with Alpha, Beta, Gamma, or Delta variants is significantly reduced or ineffective. Third vaccine doses can boost neutralization titers against Omicron, and high titers are observed in both vaccinated individuals and those infected with the Delta variant. Most potent monoclonal antibodies and antibodies under development are unable to effectively neutralize Omicron due to mutations in its Spike protein. Omicron has structural changes compared to earlier viruses and utilizes mutations that enhance its binding to ACE2, allowing for immune escape. This results in a large number of mutations in the ACE2 binding site and a rebalancing of receptor affinity similar to earlier pandemic viruses.
Letter
Medicine, General & Internal
Wanwisa Dejnirattisai et al.
Article
Multidisciplinary Sciences
Catherine J. Reynolds et al.
Summary: The study found that the initial strain of SARS-CoV-2 infection's impact on downstream immunity to heterologous variants of concern (VOCs) is unknown. After three antigen exposures, neutralization potency against different VOCs changed, and serology poorly predicted neutralizing immunity. Heterologous combinations of spike encountered during infection and vaccination shape subsequent cross-protection against VOCs.
Article
Microbiology
Allison J. Greaney et al.
Summary: Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are key in neutralizing antibody responses, and a deep mutational scanning method was used to assess the impact of all amino-acid mutations in the RBD on antibody binding with 10 human monoclonal antibodies. The study identified the clustered escape mutations in different surfaces of the RBD that correspond to structurally defined antibody epitopes, showing that even antibodies targeting the same surface can have distinct escape mutations.
CELL HOST & MICROBE
(2021)
Article
Immunology
Zhen Zhuang et al.
Summary: This study identified SARS-CoV-2-specific T cell epitopes and demonstrated the important role of virus-specific T cells in the immune response after SARS-CoV-2 infection, particularly in regulating immune responses. T cell vaccination alone partially protected SARS-CoV-2-infected mice from severe disease.
JOURNAL OF EXPERIMENTAL MEDICINE
(2021)
Article
Multidisciplinary Sciences
Katherine McMahan et al.
Summary: Adoptive transfer of purified IgG from convalescent macaques protects naive macaques against SARS-CoV-2 infection, and cellular immune responses contribute to protection against rechallenge with SARS-CoV-2. The findings suggest that relatively low antibody titres are sufficient for protection against SARS-CoV-2 in macaques, while higher antibody titres are required for treatment of SARS-CoV-2 infection.
Article
Biochemical Research Methods
Wei Bu Wang et al.
Summary: The COVID-19 pandemic has caused a global outbreak, with hopes pinned on effective vaccines and antibody treatments. However, the virus continues to mutate, with the E484K mutation potentially increasing transmissibility and reducing antibody effectiveness. Research shows that the E484K mutation enhances virus-receptor binding affinity while diminishing antibody binding strength.
JOURNAL OF MOLECULAR GRAPHICS & MODELLING
(2021)
Article
Biochemistry & Molecular Biology
Qianqian Li et al.
Summary: The 501Y.V2 variants of SARS-CoV-2 with multiple mutations are rapidly spreading from South Africa to other countries, showing reduced susceptibility to neutralizing antibodies and potential compromise of monoclonal antibodies and vaccines. Enhanced infectivity in murine ACE2-overexpressing cells suggests the possibility of transmission to mice.
Article
Biochemistry & Molecular Biology
Daming Zhou et al.
Summary: The race to develop vaccines against SARS-CoV-2 variants, such as B.1.1.7, B.1.351, and P.1, is ongoing as these variants have mutations in the spike protein, potentially leading to immune escape. A structure-function analysis of B.1.351 revealed tighter ACE2 binding and widespread evasion from monoclonal antibody neutralization, particularly driven by the E484K mutation.
Article
Microbiology
Gabriele Cerutti et al.
Summary: Structural analysis revealed that seven potent NTD-directed neutralizing antibodies target a common surface on NTD, forming a single supersite different from the recognition pattern of RBD-directed antibodies.
CELL HOST & MICROBE
(2021)
Article
Biochemistry & Molecular Biology
Shuo Feng et al.
Summary: Defined levels of SARS-CoV-2-specific binding and neutralizing antibodies elicited by the COVID-19 vaccine were identified as correlates of protection against symptomatic infection. Higher levels of immune markers were correlated with a reduced risk of symptomatic infection. The data can be used to extrapolate efficacy estimates to new populations.
Article
Multidisciplinary Sciences
Dami A. Collier et al.
Summary: The B.1.1.7 variant of SARS-CoV-2 exhibited reduced neutralization by vaccines and antibodies from recovered COVID-19 patients, with a more substantial loss seen when introducing the E484K mutation. This mutation poses a threat to the efficacy of the BNT162b2 vaccine.
Article
Multidisciplinary Sciences
Houriiyah Tegally et al.
Summary: The article describes a newly emerged lineage of SARS-CoV-2, 501Y.V2, characterized by eight mutations in the spike protein, which may result in increased transmissibility or immune escape. This lineage originated in South Africa and quickly became dominant in Eastern Cape, Western Cape, and KwaZuluNatal provinces within weeks.
Article
Biochemistry & Molecular Biology
Constantinos Kurt Wibmer et al.
Summary: The SARS-CoV-2 virus in the B.1.351 variant discovered in South Africa can evade neutralization by most antibodies when expressed, but does not affect binding by convalescent plasma. This suggests the potential for reinfection with antigenically distinct variants and predicts reduced efficacy of spike-based vaccines.
Article
Biochemistry & Molecular Biology
Xuping Xie et al.
Summary: The study found that human sera from recipients of the BNT162b2 vaccine can neutralize SARS-CoV-2 viruses containing key spike mutations from the newly emerged UK and SA variants.
Article
Multidisciplinary Sciences
Kizzmekia S. Corbett et al.
Summary: The study found that neutralizing antibody responses against several variants of concern gradually declined after vaccination with the mRNA-1273 vaccine for the SARS-CoV-2 virus. However, boosting nonhuman primates with either homologous or heterologous mRNA-1273 vaccines after 6 months resulted in increased neutralizing antibody responses across all variants of concern, which lasted for at least 8 weeks after the boost. After being challenged with the SARS-CoV-2 Beta variant 9 weeks post-boost, viral replication was low to undetectable in bronchoalveolar lavage and significantly reduced in nasal swabs in all boosted animals, indicating the potential necessity for booster vaccinations to maintain immunity and protection.
Article
Immunology
Kai Wu et al.
Summary: The study evaluated the efficacy of two updated mRNA vaccines targeting SARS-CoV-2 variants in mice. The vaccine based on B.1.351 was effective at increasing neutralizing antibody titers, while the 1:1 mix vaccine provided broad cross-variant neutralization. A third dose of vaccine significantly increased neutralization titers.
Article
Medicine, General & Internal
Eleftheria Vasileiou et al.
Summary: The study in Scotland found that the first doses of the BNT162b2 mRNA and ChAdOx1 vaccines were associated with substantial reductions in the risk of COVID-19 hospital admission, with vaccine effectiveness ranging from 88% to 91% at 28-34 days post-vaccination.
Article
Medicine, General & Internal
Victoria Jane Hall et al.
Summary: The study aimed to determine the factors associated with vaccine coverage for two COVID-19 vaccines in the UK and to document the vaccine effectiveness of the BNT162b2 mRNA vaccine among healthcare workers. Results showed that the vaccine can prevent both symptomatic and asymptomatic infections in working-age adults, with a vaccine effectiveness of 70% after the first dose and 85% after the second dose.
Article
Medicine, General & Internal
S. A. Madhi et al.
Summary: The ChAdOx1 nCoV-19 vaccine did not provide significant protection against mild-to-moderate Covid-19 caused by the B.1.351 variant, with an efficacy of 10.4%. The incidence of serious adverse events was balanced between the vaccine and placebo groups.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Ge Song et al.
Summary: This study examines the impact of pre-existing immunity to seasonal endemic coronaviruses on antibody responses to SARS-CoV-2, finding weak evidence of pre-existing cross-reactive serum antibodies in pre-pandemic donors, but evidence of pre-existing cross-reactive memory B cells activated during SARS-CoV-2 infection. Monoclonal antibodies show varying degrees of cross-reactivity with betacoronaviruses, and one neutralizing antibody specific to the S2 subunit of the S protein is identified, suggesting that pre-existing immunity to endemic coronaviruses should be considered in evaluating antibody responses to SARS-CoV-2.
NATURE COMMUNICATIONS
(2021)
Article
Multidisciplinary Sciences
Alexandra J. Spencer et al.
Summary: The study suggests that heterologous vaccination with a self-amplifying RNA vaccine and an adenoviral vectored vaccine against SARS-CoV-2 in mice leads to higher antibody responses and superior cellular immune responses compared to homologous vaccination regimens.
NATURE COMMUNICATIONS
(2021)
News Item
Medicine, General & Internal
Elisabeth Mahase
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Article
Chemistry, Multidisciplinary
Yasunori Watanabe et al.
Summary: Vaccine development targeting the SARS-CoV-2 virus focuses on the S glycoprotein as the principal target of the neutralizing immune response. Adenovirus-vectored vaccines have shown effective processing and assembly of viral antigens, mimicking the observed SARS-CoV-2 virus, making them a promising platform for SARS-CoV-2 vaccines.
ACS CENTRAL SCIENCE
(2021)
Article
Biochemistry & Molecular Biology
Chang Liu et al.
Summary: Recent study examined the neutralizing ability of monoclonal antibodies, convalescent and vaccine sera against the Indian variants B.1.617.1 and B.1.617.2, showing that the neutralization of these variants is reduced compared to the ancestral strains, without widespread antibody escape as seen in other variants like B.1.351.
Article
Medicine, General & Internal
Amy Flaxman et al.
Summary: The study shows that an extended interval before the second dose of the AstraZeneca vaccine leads to increased antibody titres, while a third dose significantly boosts antibody levels and enhances T-cell responses.
Article
Biochemistry & Molecular Biology
Angela Choi et al.
Summary: The study demonstrates that both the mRNA-1273 COVID-19 vaccine and its variant-modified booster doses are safe and effective in improving neutralizing antibody titers against various virus variants.
Article
Multidisciplinary Sciences
Teresa Aydillo et al.
Summary: The study found that previous infections with seasonal coronaviruses can affect the antibody response to SARS-CoV-2 in COVID-19 patients. While SARS-CoV-2 infection can boost pre-existing responses to other coronaviruses, this back-boosting hampers the induction of specific antibodies against SARS-CoV-2.
NATURE COMMUNICATIONS
(2021)
Article
Medicine, General & Internal
Hannah Chung et al.
Summary: The study demonstrates that two doses of mRNA covid-19 vaccines are highly effective against symptomatic infection and severe outcomes. However, the effectiveness of one dose is lower, particularly for older adults shortly after the first dose. For adults aged >=70 years, vaccine effectiveness estimates were observed to be lower for intervals shortly after one dose but were comparable to those for younger people for all intervals after 28 days.
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Article
Immunology
Benjamin Israelow et al.
Summary: Research demonstrates that both humoral and cellular immunity play a role in clearing SARS-CoV-2, and convalescent mice or mice vaccinated with mRNA are protected from infection with both the wild type virus and the B.1.351 variant. This protection is mainly mediated by antibody response rather than cellular immunity.
SCIENCE IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Qianqian Li et al.
Article
Immunology
Simon P. Graham et al.
Article
Multidisciplinary Sciences
Noe B. Mercado et al.
Article
Multidisciplinary Sciences
Neeltje van Doremalen et al.
Article
Multidisciplinary Sciences
Seth J. Zost et al.
Article
Multidisciplinary Sciences
Ching-Lin Hsieh et al.
Article
Multidisciplinary Sciences
Paul F. McKay et al.
NATURE COMMUNICATIONS
(2020)
Article
Multidisciplinary Sciences
Lizhou Zhang et al.
NATURE COMMUNICATIONS
(2020)
Article
Multidisciplinary Sciences
Yixuan J. Hou et al.
Article
Multidisciplinary Sciences
Matthew D. J. Dicks et al.
